BioNTech (NASDAQ:BNTX) and OncoC4 have had a partial clinical hold placed by the FDA on a Phase 3 study for their drug ...

The FDA has implemented a partial hold on a phase 3 non-small cell lung cancer trial run by BioNTech and OncoC4 after seeing ...

BioNTech (NASDAQ:BNTX) shares fell Friday after the company said it had been informed by partner OncoC4 that FDA placed ...

OncoC4 is taking AcroImmune—and its in-house clinical manufacturing capabilities—under its wing in an all-stock merger. Both cancer biotechs were co-founded by OncoC4 CEO Yang Liu, Ph.D., and ...

Dr Yang Liu shares his insights into the preclinical studies behind the development of drug candidates targeting the ...

ROCKVILLE, Md., Sept. 25, 2024 (GLOBE NEWSWIRE) -- OncoC4, Inc., a late-stage biopharmaceutical company developing novel medicines for cancer, and AcroImmune, a ...

ROCKVILLE, Md., Sept. 04, 2024 (GLOBE NEWSWIRE) -- OncoC4, Inc. (“OncoC4”), a late-stage biopharmaceutical company developing novel medicines for cancer and immunological diseases, today ...

Discover the major biotech partnerships, collaborations and mergers and acquisitions that made headlines in September 2024.

OncoC4, Pfizer and Regeneron. For more information, please visit www.BioNTech.com. BioNTech Forward-looking Statements This press release contains forward-looking statements within the meaning of ...

Medscape Medical News, June 30, 2023 BioNTech, OncoC4 Start Late-Stage Lung Cancer Drug Trial BioNTech and its US partner OncoC4 say they have started a late-stage study of their lung cancer ...

The addition of nivolumab to rucaparib did not lead to better progression-free survival than rucaparib monotherapy in patients with newly diagnosed, advanced, high-grade ovarian cancer (AHGOC), a ...

Sept. 25, 2024 (GLOBE NEWSWIRE) -- OncoC4, Inc., a late-stage biopharmaceutical company developing novel medicines for cancer, and AcroImmune, a biopharmaceutical company developing immunotherapy ...